• linkedin
  • Increase Font
  • Sharebar

    Small molecule RNA inhibitor shows promise in PCa


    “Targeted treatment for cancer aims to improve efficacy and safety by using agents that are tumor specific because they modulate gene networks that are selectively upregulated in tumor cells but not in healthy tissue,” said senior author Matthew D. Disney, PhD, of The Scripps Research Institute, Scripps Florida, Jupiter.

    “Our work with the microRNA-18a inhibitor is an advance in this type of precision medicine because it represents the first demonstration of a small molecule inhibitor successfully targeting an oncogenic noncoding RNA in prostate cancer cells. Moving ahead, we are working to optimize the molecule so that it will be effective when tested in vivo in an animal model. The ultimate question we are trying to address is, how quickly can we get this to patients?”

    Also see - PCa immunotherapy: Response better when given before ADT

    Dr. Disney and colleagues in his laboratory have been working for more than 10 years to design small molecules that act as selective inhibitors of oncogenic noncoding RNAs. Their search is based on a reverse assay approach. It begins with the creation of small molecules that are screened for their binding profiles to a library of about 100,000 small RNA motifs, which do not necessarily have any known association with cancer. Positive interactions are mined against genomic RNAs to identify lead therapeutic candidates using a computational approach created by Dr. Disney and colleagues.

    “In identifying Targapremir-18a as a possible treatment for prostate cancer, we did not develop it with the aim of targeting prostate cancer. Rather, prostate cancer found us through our screening process in which we found that Targapremir-18a bound with high affinity and selectivity to microRNA-18A,” Dr. Disney told Urology Times.

    Dr. Disney and colleagues have already developed other small molecule RNA inhibitors as potential targeted treatments for other types of cancers that have demonstrated promising activity when tested both in vitro and in animal models. Small molecule RNA inhibitors are also being developed as targeted treatments for other RNA-associated diseases.

    More on Targeted Therapy:

    Prostate Ca: Immunotherapy consensus statement published

    High-grade bladder Ca: New data improve risk stratification

    RCC: Multiple pathways provide therapeutic targets

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results